###begin article-title 0
Circulating Precursor Levels of Endothelin-1 and Adrenomedullin, Two Endothelium-Derived, Counteracting Substances, in Sepsis
###end article-title 0
###begin p 1
Philipp Schuetz and Mirjam Christ-Crain contributed equally to this work.
###end p 1
###begin p 2
The authors wish to thank the Laboratory of Chemical Pathology of the University Hospital Basel and Prof. Peter Huber, Dr. Marc A. Viollier, and Prof. Rudolf Ritz.
###end p 2
###begin p 3
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 3
###begin p 4
###xml 872 873 872 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1055 1056 1055 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1167 1168 1167 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1353 1354 1353 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1394 1395 1394 1395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1435 1436 1435 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1460 1461 1460 1461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1496 1497 1496 1497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 361 369 <span type="species:ncbi:9606">patients</span>
###xml 507 515 <span type="species:ncbi:9606">patients</span>
###xml 1634 1642 <span type="species:ncbi:9606">patients</span>
Plasma levels of endothelin-1 (ET-1) and adrenomedullin (ADM), two opposingly acting peptides, correlate with mortality in endotoxemia, but their measurement is cumbersome. New sandwich assays have been introduced that measure more stable precursor fragments. The objective of this study was to investigate the counterplay of their precursor peptides in septic patients and to compare them with disease severity and other biomarkers. Blood samples of an observational study in 95 consecutive critically ill patients admitted to the intensive care unit (ICU) were analyzed. CT-proET-1 and MR-proADM concentrations on admission were measured using new sandwich immunoassays. Depending on the clinical severity of the infection, both CT-proET-1 and MR-proADM levels exhibited a gradual increase from Systemic Inflammatory Response Syndrome (SIRS) to sepsis and septic shock (p < .001). Compared to the group of survivors, the group of non-survivors had higher median values of MR-proADM (5.7 nmol/L [range 0.4 to 21.0] versus 1.9 nmol/L [range 0.3 to 17.1], p < .02) and similar CT-proET-1 levels (56.0pmol/L [range 0.5 to 271.0] versus 54.1pmol/L [range 1.0 to 506.0], p = .86). Receiver operating characteristics (ROC) curve analysis showed a higher prognostic accuracy of the calculated ratio of both counteracting substances as compared to CT-proET-1 (p = 0.001) and C-reactive protein (CRP) (p = .001) and in the range of MR-proADM (p = .51), procalcitonin (p = 0.22), and the APACHE II score (p = .61). Endothelin-1 and adrenomedullin precursor peptides gradually increase with increasing severities of infection in critically ill patients. The ratio of the two counteracting peptides correlates with mortality and shows aprognostic accuracy to predict adverse outcome comparable to the APACHE II score.
###end p 4
###begin p 5
###xml 410 420 410 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">Levin 1995</xref>
###xml 422 440 422 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">Hinson et al. 2000</xref>
###xml 442 460 442 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">Landry et al. 2004</xref>
###xml 462 486 462 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Christ-Crain et al. 2005</xref>
###xml 611 621 611 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">Levin 1995</xref>
###xml 623 647 623 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">Tschaikowsky et al. 2000</xref>
###xml 801 825 801 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Christ-Crain et al. 2005</xref>
###xml 827 831 827 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">2006</xref>
###xml 968 984 968 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">Ueda et al. 1999</xref>
###xml 986 1005 986 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">Brauner et al. 2000</xref>
###xml 1193 1211 1193 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">Hinson et al. 2000</xref>
###xml 1213 1221 1213 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">Eto 2001</xref>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
The main cause of death in patients with sepsis is multiple organ failure and volume refractory hypotension, which are frequently complicated by impaired tissue perfusion and myocardial depression. Endothelin-1 (ET-1) and adrenomedullin (ADM), two endothelium-derived vasoactive peptides, have attracted interest as physiological key mediators in vascular tone regulation in sepsis and cardiovascular disease (Levin 1995; Hinson et al. 2000; Landry et al. 2004; Christ-Crain et al. 2005). ET-1, a 21-amino acid peptide, is mainly derived by vascular endothelial cells and acts as a very potent vasoconstrictor (Levin 1995; Tschaikowsky et al. 2000). Conversely, ADM is a potent vasodilator, which assures blood supply to the individual organ and has been shown to be increased in systemic infections (Christ-Crain et al. 2005, 2006). Both peptides correlate with mortality and, thus, have been put forward as prognostic markers of disease severity in septic syndrome (Ueda et al. 1999; Brauner et al. 2000). However, the methodological reliability of plasma ET-1 and ADM measurements is challenging because of their rapid clearance from the circulation, limiting their use in common practice (Hinson et al. 2000; Eto 2001). Therefore, new sandwich assays have been introduced that measure the more stable precursor fragments CT-proET-1 and MR-proADM. Unlike the mature peptides, these fragments can be detected for hours in the circulation. Because of the stoichiometrical generation, these "prohormones" represent the release of the active peptide, a situation similar to that of C-peptide and insulin. Thus, these fragments can be used to indirectly assess the release of the mature peptides in physiological and pathological conditions.
###end p 5
###begin p 6
###xml 217 225 <span type="species:ncbi:9606">patients</span>
To investigate the interaction and a possible predictive value of the precursor peptides of ET-1 and ADM in sepsis, we measured CT-proET-1 and MR-proADM in a previously well-described cohort of medical intensive care patients and compared those levels with traditional biomarkers, a disease severity score, and medical outcome.
###end p 6
###begin title 7
MATERIAL AND METHODS
###end title 7
###begin title 8
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 8
###begin p 9
###xml 583 602 583 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Muller et al. 2000a</xref>
###xml 604 609 604 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">2000b</xref>
###xml 611 615 611 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">2001</xref>
###xml 617 621 617 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">2002</xref>
###xml 623 647 623 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Christ-Crain et al. 2005</xref>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
###xml 364 372 <span type="species:ncbi:9606">patients</span>
The present study evaluated asserved plasma samples of 95 out of a cohort of 101 consecutive critically ill patients admitted to the medical intensive care unit (ICU) of the University Hospital of Basel, Switzerland, between September 1996 and June 1997. The primary end point was the assessment of the prognostic value of endocrine dysfunctions in critically ill patients ("PEDCRIP" study). Details of the characteristics of the study population, study design, the diagnostic criteria, and the levels of different markers of inflammation and infection have been reported in detail (Muller et al. 2000a, 2000b, 2001, 2002; Christ-Crain et al. 2005).
###end p 9
###begin p 10
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 154 162 <span type="species:ncbi:9606">Patients</span>
###xml 627 635 <span type="species:ncbi:9606">patients</span>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
Briefly, over a 9-month period, 101 consecutive patients, including neutropenic and immunosuppressed patients, admitted to the medical ICU were included. Patients were followed until hospital discharge or death. Vital signs, clinical status, and severity of disease were assessed daily and the commonly used physiological APACHE II score was calculated. For the purpose of this study, only data collected during the first 24 h of admission were assessed. The primary end point was in-hospital mortality. Pulmonary artery catheter was not routinely inserted. When feasible, consent was obtained prior to enrollment in conscious patients; otherwise, the consent was obtained from the patients' next of kin. The study protocol had prior approval by the hospital institute ethical review board.
###end p 10
###begin p 11
###xml 178 194 178 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">Bone et al. 1992</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 260 267 <span type="species:ncbi:9606">patient</span>
Patients were classified at the time of blood collection into sepsis, septic shock and Systemic Inflammatory Response Syndrome (SIRS) using international, standardized criteria (Bone et al. 1992). In case of uncertainty of infection, a complete, retrospective patient chart review including results of microbiological cultures, chest radiographs, and, when available, postmortem examination reports, was performed by an infectious disease specialist. An isolated microorganism was considered to be pathogenic if recovered within a 24-h period before or after the onset of the systemic response. Microbiological tests and antibiotic therapy were prescribed by physicians on duty according to the usual practice, without interference by the research team.
###end p 11
###begin title 12
Assays
###end title 12
###begin p 13
###xml 239 240 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 555 579 549 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Christ-Crain et al. 2005</xref>
###xml 581 605 575 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Morgenthaler et al. 2005</xref>
###xml 607 625 601 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">Struck et al. 2005</xref>
###xml 627 652 621 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">Papassotiriou et al. 2006</xref>
###xml 1062 1086 1056 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Morgenthaler et al. 2005</xref>
###xml 1088 1113 1082 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">Papassotiriou et al. 2006</xref>
Results of the routine blood analyses were recorded. Plasma on admission was collected at the time of blood sampling in plastic tubes containing ethylenediaminetetraacetic acid (EDTA). They were placed on ice and then centrifuged at 3000 xg; and plasma was frozen at -70degreesC until assayed. Pro-endothelin-1 fragments (CT-proET-1) and mid-regional pro-adrenomedullin (MR-proADM) were detected with two new sandwich immunoassays (Sevacon LIA and Sevadil LIA, respectively; B.R.A.H.M.S AG, Hennigsdorf/Berlin, Germany), as described in detail elsewhere (Christ-Crain et al. 2005; Morgenthaler et al. 2005; Struck et al. 2005; Papassotiriou et al. 2006). Briefly, both immunoassays employ two polyclonal antibodies to the amino acids 168-212 of pre-pro-endothelin-1 and amino acids 45-92 of pre-pro-adrenomedullin MR-proADM (amino acids 45 to 92) and have analytical detection limits of 0.4 and 0.08 nmol/L, respectively. Values for both analytes followed a Gaussian distribution in healthy individuals without significant differences between males and females (Morgenthaler et al. 2005; Papassotiriou et al. 2006).
###end p 13
###begin p 14
###xml 592 600 <span type="species:ncbi:9606">patients</span>
Procalcitonin was measured using LUMITest PCT (B.R.A.H.M.S AG) with a functional assay sensitivity of around 0.3 to 0.5 ng/mL. C-reactive protein (CRP) was measured by an enzyme immunoassay (EMIT; Merck Diagnostica, Zurich, Switzerland), where a value of > 10 mg/L was considered to be abnormally elevated. All assays showed linear dilution, and undisturbed recovery of the analyte after pooling of samples or addition of synthetic analyte. The laboratory technician who measured CT-proET-1, MR-proADM, procalcitonin, and CRP was at a different site and blinded to the characteristics of the patients and the characteristics of the study.
###end p 14
###begin title 15
Statistical Analysis
###end title 15
###begin p 16
###xml 138 139 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 492 493 492 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Frequency comparison was done by chi-square test. Two-group comparison of not normally distributed data was performed by the Mann-Whitney U test. For multigroup comparisons, Kruskal-Wallis one-way analysis of variance with least square difference for post hoc comparison was used. Correlation analyses were performed by using Spearman's rank correlation. Levels that were nondetectable were assigned a value equal to the lower limit of detection for the assay. All testing was two-tailed and p values less than .05 were considered to indicate statistical significance. All calculations including receiver operating characteristics (ROC) were performed using Stata 9.2 (Stata, College Station, TX).
###end p 16
###begin title 17
RESULTS
###end title 17
###begin title 18
###xml 35 43 <span type="species:ncbi:9606">Patients</span>
Descriptive Characteristics of the Patients
###end title 18
###begin p 19
###xml 271 278 269 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 360 368 <span type="species:ncbi:9606">patients</span>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
###xml 534 542 <span type="species:ncbi:9606">patients</span>
###xml 572 580 <span type="species:ncbi:9606">patients</span>
The mean age of the 95 patients included in this study was 57 (range 23 to 86) years. On admission, the mean APACHE II score was 21 +/- 8 points. The median length of stay in the medical ICU was 4 days (range 0.2 to 60 days). The diagnoses on admission are summarized in Table 1. SIRS without infection was diagnosed in 47 patients. Sepsis was diagnosed in 48 patients (including 15 patients with septic shock). The principal site of infection was the lung. The need for blood pressure support with vasoactiva on admission was 28% in patients with SIRS and 52% and 80% in patients with sepsis and septic shock, respectively.
###end p 19
###begin p 20
Clinical diagnosis and site of infection
###end p 20
###begin p 21
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
One patient can have more than one diagnosis. Therefore, the total exceeds the absolute number of patients.
###end p 21
###begin p 22
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
The in-hospital mortality rate of all patients was 22% of the 48 patients admitted with sepsis, 12 died (25%) of multiorgan failure, whereas 9 out of the 47 patients with SIRS (19%) did not survive the hospital stay.
###end p 22
###begin title 23
CT-proET-1 and MR-proADM Levels and Severity of the Disease
###end title 23
###begin p 24
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 332 333 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 805 806 805 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 817 818 817 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 888 889 888 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1047 1048 1047 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1055 1056 1055 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1079 1080 1079 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1119 1120 1119 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1128 1129 1128 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1211 1212 1211 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1219 1220 1219 1220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1234 1235 1234 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1242 1243 1242 1243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1273 1274 1273 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1282 1283 1282 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1317 1318 1317 1318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1325 1326 1325 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1422 1423 1422 1423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1430 1431 1430 1431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 343 351 <span type="species:ncbi:9606">Patients</span>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
###xml 490 498 <span type="species:ncbi:9606">patients</span>
###xml 760 768 <span type="species:ncbi:9606">patients</span>
###xml 783 791 <span type="species:ncbi:9606">patients</span>
###xml 835 843 <span type="species:ncbi:9606">patients</span>
###xml 860 868 <span type="species:ncbi:9606">patients</span>
###xml 945 953 <span type="species:ncbi:9606">patients</span>
###xml 1171 1179 <span type="species:ncbi:9606">patients</span>
Figure 1 shows CT-proET-1 and MR-proADM values of all 95 critically ill patients on admission according to severity of disease (SIRS, sepsis, and septic shock). Depending on the clinical severity of the infection, MR-proADM and CT-proET-1 levels exhibited a gradual increase from the group with SIRS to the group with septic shock (p < .001). Patients with SIRS had median CT-proET-1 levels of 23.1 pmol/L (range 0.5 to 158.0), patients with sepsis of 64.3 pmol/L (range 2.0 to 271.0), and patients with septic shock of 131.6 pmol/L (range 3.0 to 506.0). The respective MR-proADM levels were (range 0.3 to 3.7), 2.6 (range 0.4 to 13.8), and 8.0 (range 0.9 to 21.0) nmol/L. Post hoc analysis for CT-proET-1 and MR-proADM showed a significant difference between patients with SIRS and patients with sepsis (p < .01 and p < .001) and for patients with sepsis and patients with septic shock (p < .05 and p < .003). Baseline CT-proET-1 values of all patients demonstrated a significant correlation with other markers of infection, i.e., procalcitonin (r =.39, p < .05) and CRP (0.35, p < .05), and with mean blood pressure (r =-.25, p < .05). Baseline MR-proADM levels of all patients correlated with procalcitonin (r =.40, p < .05), CRP (r =.35, p < .05), mean blood pressure (r =-.29, p < .05), and the APACHE II score (r =.41, p < .05). There was a significant correlation between the two peptides CT-proET-1 and MR-proADM (r =.54, p < .001).
###end p 24
###begin p 25
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 86 94 <span type="species:ncbi:9606">Patients</span>
CT-proET-1 and MR-proADM values in all patients according to the severity of disease. Patients' data on admission to the ICU were grouped according to the severity of the disease following consensus criteria in groups with "SIRS, but no sepsis," "sepsis," and "septic shock." Squares denote median values and whiskers indicate 25th and 75th percentiles.
###end p 25
###begin title 26
###xml 51 59 <span type="species:ncbi:9606">Patients</span>
CT-proET-1 and MR-proADM Levels and Outcome of All Patients
###end title 26
###begin p 27
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 404 405 404 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 567 568 567 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 712 713 712 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Figure 2 shows CT-proET-1 levels, MR-proADM levels and the calculated ratio of both precursor peptides (CT-proET-1/MR-proADM ratio) of all survivors and nonsurvivors with SIRS, sepsis, and septic shock on admission. The median CT-proET-1 value in the group of nonsurvivors (54.1 pmol/L [range 1.0 to 506.0]) was not significantly different from the group of survivors (56.0 pmol/L [range 0.5 to 271.0]), p =.87. In contrast, nonsurvivors had higher median values of MR-proADM (5.7 nmol/L [range 0.4 to 21.0] as compared to survivors (1.9 nmol/L [range 0.3 to 17.1]), p < .02. Nonsurvivors had a lower median CT-proET1/MR-ADM ratio (12.0 [range 0.5 to 44.6]) as compared to survivors (29.0 [range 0.7 to 127.2]), p < .002.
###end p 27
###begin p 28
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
CT-proET-1-, MR-proADM, and the calculated ratio in surviving as compared to nonsurviving patients. Data from all patients on admission are shown. Squares denote median values, boxes represent 25th to 75th percentiles and whiskers indicate the range.
###end p 28
###begin p 29
###xml 104 105 104 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 310 311 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 486 487 486 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
Post hoc analysis of those patients with sepsis and in need for blood pressure support with vasoactiva (n = 30) showed higher MR-proADM values (9.6 [range 0.8 to 21.0] versus 3.4 [range 0.55 to 17.1]) and lower CT-proET-1 values (70.9 [range 3.0 to 175.0] versus 93 [range 2.0 to 506]) for surviving patients (n =21) as compared to nonsurvivors. The calculated CT-proET1/MR-proADM ratio was significantly lower in non-survivors (6.8 [range 0.5 to 16.5] versus 25.7 [range 2.3 to 58.2], p < .01).
###end p 29
###begin p 30
###xml 195 196 195 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</italic>
###xml 187 196 187 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3<italic>a</italic></xref>
###xml 310 311 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
###xml 302 311 302 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3<italic>b</italic></xref>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
###xml 678 686 <span type="species:ncbi:9606">patients</span>
###xml 786 794 <span type="species:ncbi:9606">patients</span>
###xml 1003 1011 <span type="species:ncbi:9606">patients</span>
To illustrate and compare the predictive value of CT-proET1, MR-proADM and the calculated ratio of the two peptides of all 95 critically ill patients with SIRS, sepsis, and septic shock (Figure 3a) and for all 30 patients with sepsis and in need of blood pressure support with vasoactiva on admission (Figure 3b), we performed a receiver operating characteristic (ROC) plot analysis. ROC plots are graphical plots of the sensitivity and the specificity of a binary classifier system for all cut-off points of a diagnostic or prognostic test and its overall performance is expressed as the area under the ROC curve (AUC). For this analysis, sensitivity was calculated with those patients who did not survive their disease during the hospital stay and specificity was assessed with those patients who did survive. For comparison, the same ROC plot analysis was performed for different prognostic markers, namely procalcitonin, CRP, and the APACHE II score. ROC analysis for survival of all critically ill patients revealed AUCs of 0.49 for CT-proET-1, 0.67 for MRproADM, 0.73 for the CT-proET-1/MR-proADM ratio, 0.69 for the APACHE II score, 0.62 for procalcitonin, and 0.58 for CRP.
###end p 30
###begin p 31
###xml 277 278 277 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 306 307 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 673 674 673 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</italic>
###xml 698 699 698 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 798 799 798 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 835 836 835 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 872 873 872 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
###xml 981 982 981 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1060 1061 1060 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1096 1097 1096 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 171 179 <span type="species:ncbi:9606">patients</span>
###xml 688 696 <span type="species:ncbi:9606">patients</span>
###xml 883 891 <span type="species:ncbi:9606">patients</span>
Receiver operating curve (ROC) analysis of CT-proET1, MRproADM, the CT-proET1/MR-proADM ratio and the APACHE II score with respect to outcome prediction of critically ill patients. Receiver operating characteristic (ROC) plots are graphical plots illustrating the sensitivity (y-axis) and the specificity (x -axis) for all cut-off points of a diagnostic or prognostic test. The overall performance and a summary measure of the diagnostic accuracy of a test can be expressed as the area under the ROC curve (AUC). Note that an AUCof 0.50 means that the diagnostic accuracy in question is equivalent to that which would be obtained by flipping a coin (i.e., random chance). (a) Data of all patients (n = 95) with SIRS and sepsis on admission to the ICU. Sensitivity was calculated with nonsurvivors (n = 21), specificity with survivors (n = 74) during their hospital stay. (b) Data of patients with sepsis (including septic shock) in need for blood pressure support with vasoactiva (n = 30) on admission to the ICU. Sensitivity was calculated with nonsurvivors (n = 9), specificity with survivors (n = 21) during their hospital stay.
###end p 31
###begin p 32
###xml 3 11 <span type="species:ncbi:9606">patients</span>
In patients with sepsis and in need of blood pressure support, the AUC for the CT-proET-1, MR-proADM, CT-proET-1/MR-proADM ratio, and the APACHE II score were 0.49, 0.76, 0.81, and 0.60, respectively.
###end p 32
###begin p 33
###xml 507 514 507 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 10 18 <span type="species:ncbi:9606">patients</span>
In all 95 patients, the optimal threshold for the CT-proET-1/MR-proADM ratio was at 11. At this cut-off, the sensitivity for the correct prediction of death was 71.4% and the specificity was 71.6%. In comparison, the APACHE II score was also predictive for prognosis but gave lower values for the specificity as compared to the ET1/ADM ratio. The prognostic accuracies and likelihood ratios for the CT-proET1/MR-proADM ratio and the APACHE II score at different cut-offs in diagnosing survival are shown in Table 2.
###end p 33
###begin p 34
###xml 135 143 <span type="species:ncbi:9606">patients</span>
Sensitivity, specificity, and likelihood ratios of the APACHE II score and the calculated CT-proET-1/MR-proADM ratio in critically ill patients
###end p 34
###begin title 35
DISCUSSION
###end title 35
###begin p 36
###xml 149 157 <span type="species:ncbi:9606">patients</span>
This study found a gradual about eightfold increase of both endothelium-derived precursor peptides, CT-proET-1 and MRproADM, in the plasma of septic patients with increasing severity of infection. Interestingly, the interplay of the two counteracting substances, expressed as the ratio between CT-proET-1 and MR-proADM, correlated with mortality and had a similar prognostic accuracy as compared to the APACHE II score.
###end p 36
###begin p 37
###xml 375 394 375 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">Grandel et al. 2003</xref>
###xml 396 414 396 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">Peters et al. 2003</xref>
###xml 681 699 681 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">Hinson et al. 2000</xref>
###xml 701 719 701 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">Struck et al. 2004</xref>
###xml 962 984 962 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">Kedzierski et al. 2001</xref>
In sepsis, microorganisms entering the bloodstream may release their toxins, resulting in a host-derived mediator response activating an inflammatory cascade of various peptides. Accumulating evidence indicates a major role for different vasoactive substances causing dysregulation of the endothelium and consecutive collapse of blood pressure and microvascular homeostasis (Grandel et al. 2003; Peters et al. 2003). The two endothelium-derived peptides ET-1 and ADM have been suggested as two pivotal mediators in this process of vascular tone regulation. ADM contributes to the extensive vasodilatation and hypotension often seen in severe sepsis and especially in septic shock (Hinson et al. 2000; Struck et al. 2004). Conversely, with its potent vasoconstrictor properties, the vascular tissue-wide production of ET-1 counteracts this vasodilatation and hypotension and therefore assures blood pressure homeostasis and blood supply to the individual organs (Kedzierski et al. 2001). Accordingly, in our study both precursor peptides were markedly increased in different severities of sepsis and both substances correlated with mean blood pressure.
###end p 37
###begin p 38
###xml 135 154 135 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">Brauner et al. 2000</xref>
###xml 258 274 258 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">Ueda et al. 1999</xref>
###xml 276 300 276 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Christ-Crain et al. 2005</xref>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
###xml 392 400 <span type="species:ncbi:9606">patients</span>
Brauner and coworkers demonstrated an association of ET1levels and mortality in septic patients only when measured 6h after admission (Brauner et al. 2000). Similarly, ADM has been suggested to serve as an outcome predictor in patients with SIRS and sepsis (Ueda et al. 1999; Christ-Crain et al. 2005). In our study, baseline MR-proADM levels but not ET-1 levels were significantly higher in patients not surviving their disease as compared to those who did. A possible reason for the different results between our study and the study by Brauner et al. was that we did not measure the dynamics of these peptides, especially ET-1, in the course of disease. However, a biomarker whose prognostic value is only present at 6 h and not at earlier or later time points is arguably of minor clinical help.
###end p 38
###begin p 39
###xml 970 988 970 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">Wagner et al. 1984</xref>
###xml 1141 1160 1141 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">Abraham et al. 2005</xref>
###xml 1162 1175 1162 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">Parrillo 2005</xref>
###xml 1288 1309 1288 1309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">Polderman et al. 2001</xref>
###xml 1311 1328 1311 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">Booth et al. 2005</xref>
###xml 536 544 <span type="species:ncbi:9606">patients</span>
###xml 677 685 <span type="species:ncbi:9606">patients</span>
###xml 960 968 <span type="species:ncbi:9606">patients</span>
###xml 1441 1449 <span type="species:ncbi:9606">patients</span>
###xml 1922 1930 <span type="species:ncbi:9606">patients</span>
###xml 2126 2134 <span type="species:ncbi:9606">patients</span>
In this study, we used ROC curves comparing sensitivities and specificities at any given cut-off point to compare the summary measure of the prognostic accuracy of the precursor peptides as compared to the clinical APACHE II score. Interestingly, the calculated ratio between the potent vasoconstrictor CT-proET-1 and its vasodilating opponent MR-proADM improved the prognostic accuracy to predict mortality as compared to each peptide alone and was similar to the routinely used physiological APACHE II score. In critically ill septic patients, the risk-benefit ratio of a specific therapy might depend on the extent of the disease severity. For example, only the subgroup of patients with the highest risk of dying, reflected in an APACHE II score of more than 24 points, is benefiting from the administration of activated protein C (Drotrecogin alpha). The APACHE II score was originally suggested not to be used for individual outcome prediction of sepsis patients (Wagner et al. 1984). The use of the APACHE II score for individual treatment decisions can be problematic because of the difficulties of determining the score clinically (Abraham et al. 2005; Parrillo 2005). Calculating clinical scores is time consuming, sometimes complex, and shows a high interobserver variability (Polderman et al. 2001; Booth et al. 2005). However, despite its inherent limitations, outcome predictors are clearly helpful in identifying those septic patients with a high risk of death, who are more likely to benefit from intervention treatment. In our opinion, it is advisable to base the difficult task of prognostic assessment and treatment decisions on several parameters that each mirror different physiological aspects. In this context, upon availability in the routine setting, determination of the CT-proET-1 and MRproADM ratio might prove to be an additional helpful tool for a broader prognostic classification of septic patients. With its higher specificity as compared to the APACHE II score, it might provide an additional margin of safety. We endorse further studies to validate our results and to prospectively identify patients in whom these peptides could possibly improve the APACHE II score.
###end p 39
###begin p 40
###xml 169 187 169 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">Rongen et al. 1994</xref>
###xml 459 480 459 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">Weitzberg et al. 1991</xref>
###xml 897 915 897 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">Hinson et al. 2000</xref>
###xml 917 925 917 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">Eto 2001</xref>
###xml 1178 1196 1178 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">Struck et al. 2004</xref>
###xml 1150 1158 <span type="species:ncbi:9606">patients</span>
ET-1 originates from a larger precursor peptide, which is first proteolytically processed to big ET-1 and further excised by the action of endothelin-converting enzyme (Rongen et al. 1994). In this study the precursor fragment of ET-1 was chosen to monitor, because pro-ET-1 fragments can be detected for hours after its cleavage in the circulation, in contrast to ET-1, which is eliminated within minutes and therefore escapes detection in clinical routine (Weitzberg et al. 1991). Importantly, CT-proET-1 fragments are produced in a stoichiometrical ratio to ET-1 and can thus be used to indirectly assess the release of ET-1 in physiological and pathological conditions. For the same reasons we measured MR-proADM instead of mature ADM. The measurement of mature ADM is technically challenging and the reliable measurement almost impossible, because it is rapidly cleared from the circulation (Hinson et al. 2000; Eto 2001). Recently, the more stable mid-regional fragment of pro-adrenomedullin (MR-proADM) comprising amino acids 45 to 92, which directly reflects levels of the rapidly degraded active peptide ADM, was identified in the plasma of patients with septic shock (Struck et al. 2004) and a technically very robust and reliable assay for this peptide was subsequently developed.
###end p 40
###begin p 41
Our study has limitations. First, as an observational study, a contamination bias is obvious and we interpret our results as preliminary and hypothesis generating. Larger studies should be done to confirm the external validity of our findings. Therefore, daily measurements of blood values including the CT-proET-1/MR-proADM ratio and invasive assessment of macro-and microvascular tone and cardiac function should be preformed. Second, a single biomarker will always oversimplify the interpretation of important variables and, therefore, the CT-proET-1/MR-proADM ratio is meant to contribute to, rather than supersede, clinician's judgment and the validated APACHE II score.
###end p 41
###begin p 42
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 255 263 <span type="species:ncbi:9606">patients</span>
In conclusion, baseline endothelin-1 and adrenomedullin precursor levels are significantly increased in patients with sepsis and septic shock. Combining both counteracting peptides in a ratio reflecting vasomotor status correlates with mortality in these patients. With a high specificity to predict bad outcome, the CT-proET1/MR-proADM ratio could complement the APACHE II score.
###end p 42
###begin title 43
REFERENCES
###end title 43
###begin article-title 44
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
###end article-title 44
###begin article-title 45
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
###end article-title 45
###begin article-title 46
Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine
###end article-title 46
###begin article-title 47
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Application of a population-based severity scoring system to individual patients results in frequent misclassification
###end article-title 47
###begin article-title 48
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Circulating endothelin-1 and tumor necrosis factor-alpha: Early predictors of mortality in patients with septic shock
###end article-title 48
###begin article-title 49
Mid-regional proadrenomedullin as a prognostic marker in sepsis: An observational study
###end article-title 49
###begin article-title 50
Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]
###end article-title 50
###begin article-title 51
A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides
###end article-title 51
###begin article-title 52
Endothelial responses to bacterial toxins in sepsis
###end article-title 52
###begin article-title 53
Adrenomedullin, a multifunctional regulatory peptide
###end article-title 53
###begin article-title 54
Endothelin system: The double-edged sword in health and disease
###end article-title 54
###begin article-title 55
Insights into shock
###end article-title 55
###begin article-title 56
Endothelins
###end article-title 56
###begin article-title 57
Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay
###end article-title 57
###begin article-title 58
Disordered calcium homeostasis of sepsis: Association with calcitonin precursors
###end article-title 58
###begin article-title 59
Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit
###end article-title 59
###begin article-title 60
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients
###end article-title 60
###begin article-title 61
###xml 77 85 <span type="species:ncbi:9606">patients</span>
High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: Association of high decoy receptor levels with glucocorticoid administration
###end article-title 61
###begin article-title 62
###xml 94 99 <span type="species:ncbi:9606">human</span>
Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma
###end article-title 62
###begin article-title 63
Severe sepsis and therapy with activated protein C
###end article-title 63
###begin article-title 64
Molecular basis of endothelial dysfunction in sepsis
###end article-title 64
###begin article-title 65
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis
###end article-title 65
###begin article-title 66
Accuracy and reliability of APACHE II scoring in two intensive care units: Problems and pitfalls in the use of APACHE II and suggestions for improvement
###end article-title 66
###begin article-title 67
Endothelium and the regulation of vascular tone with emphasis on the role of nitric oxide. Physiology, pathophysiology and clinical implications
###end article-title 67
###begin article-title 68
Proteolytic processing pattern of the endothelin-1 precursor in vivo
###end article-title 68
###begin article-title 69
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Identification of an adrenomedullin precursor fragment in plasma of sepsis patients
###end article-title 69
###begin article-title 70
###xml 21 29 <span type="species:ncbi:9606">patients</span>
Endothelin in septic patients: Effects on cardiovascular and renal function and its relationship to proinflammatory cytokines
###end article-title 70
###begin article-title 71
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome
###end article-title 71
###begin article-title 72
Initial international use of APACHE. An acute severity of disease measure
###end article-title 72
###begin article-title 73
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Elevated plasma levels of endothelin in patients with sepsis syndrome
###end article-title 73

